Elul Batya, Wools-Kaloustian Kara K, Wu Yingfeng, Musick Beverly S, Nuwagaba-Biribonwoha Harriet, Nash Denis, Ayaya Samuel, Bukusi Elizabeth, Okong Pius, Otieno Juliana, Wabwire Deo, Kambugu Andrew, Yiannoutsos Constantin T
*Department of Epidemiology, Mailman School of Public Health, Columbia University, ICAP at Columbia University, New York, NY; †Division of Infectious Diseases, Indiana University School of Medicine, Indianapolis, IN; ‡ICAP at Columbia University, New York, NY; §Department of Biostatistics, Indiana University School of Medicine, Indianapolis, IN; ‖Epidemiology and Biostatistics Program, CUNY School of Public Health, New York, NY; ¶Academic Model for Prevention and Treatment of HIV (AMPATH), Eldoret, Kenya; #Family AIDS Care and Education Services, Nairobi, Kenya; **Nsambya Hospital, Uganda Matyr's University, Kampala, Uganda; ††Nyanza General Hospital, Kisumu, Kenya; ‡‡Makerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda; §§Infectious Diseases Institute, Kampala, Uganda; and ‖‖Department of Biostatistics, Indiana University Fairbanks School of Public Health, Indianapolis, IN.
J Acquir Immune Defic Syndr. 2016 Jul 1;72(3):324-32. doi: 10.1097/QAI.0000000000000963.
Scale-up of triple-drug antiretroviral therapy (ART) in Africa has transformed the context of childbearing for HIV-positive women and may impact pregnancy incidence in HIV programs.
Using observational data from 47,313 HIV-positive women enrolled at 26 HIV clinics in Kenya and Uganda between 2001 and 2009, we calculated the crude cumulative incidence of pregnancy for the pre-ART and on-ART periods. The causal effect of ART use on incident pregnancy was assessed using inverse probability weighted marginal structural models, and the relationship was further explored in multivariable Cox models.
Crude cumulative pregnancy incidence at 1 year after enrollment/ART initiation was 4.0% and 3.9% during the pre-ART and on-ART periods, respectively. In marginal structural models, ART use was not significantly associated with incident pregnancy [hazard ratio = 1.06; 95% confidence interval (CI): 0.99 to 1.12]. Similarly, in Cox models, there was no significant relationship between ART use and incident pregnancy (cause-specific hazard ratio: 0.98; 95% CI: 0.91 to 1.05), but effect modification was observed. Specifically, women who were pregnant at enrollment and on ART had an increased risk of incident pregnancy compared to those not pregnant at enrollment and not on ART (cause-specific hazard ratio: 1.11; 95% CI: 1.01 to 1.23).
In this large cohort, ART initiation was not associated with incident pregnancy in the general population of women enrolling in HIV care but rather only among those pregnant at enrollment. This finding further highlights the importance of scaling up access to lifelong treatment for pregnant women.
非洲扩大三联抗逆转录病毒疗法(ART)已经改变了HIV阳性女性的生育环境,并且可能会影响HIV项目中的妊娠发生率。
利用2001年至2009年间在肯尼亚和乌干达26家HIV诊所登记的47313名HIV阳性女性的观察数据,我们计算了ART治疗前和治疗期间妊娠的粗累积发生率。使用逆概率加权边际结构模型评估ART使用对妊娠发生率的因果效应,并在多变量Cox模型中进一步探讨这种关系。
在登记/开始ART治疗1年后,治疗前和治疗期间的粗累积妊娠发生率分别为4.0%和3.9%。在边际结构模型中,ART使用与妊娠发生率无显著关联[风险比=1.06;95%置信区间(CI):0.99至1.12]。同样,在Cox模型中,ART使用与妊娠发生率之间也没有显著关系(病因特异性风险比:0.98;95%CI:0.91至1.05),但观察到了效应修正。具体而言,与登记时未怀孕且未接受ART治疗的女性相比,登记时怀孕且接受ART治疗的女性发生妊娠的风险增加(病因特异性风险比:1.11;95%CI:1.01至1.23)。
在这个大型队列中,开始ART治疗与接受HIV护理的女性总体人群中的妊娠发生率无关,而仅与登记时怀孕的女性有关。这一发现进一步凸显了扩大孕妇获得终身治疗机会的重要性。